Table 1 Baseline characteristics of CRC patients.

From: Preoperative pan-immuno-inflammatory values and albumin-to-globulin ratio predict the prognosis of stage I–III colorectal cancer

Characteristics

Overall patients N = 650

Training cohort N = 470

Validation cohort N = 180

Age, median (IQR)

61 (52, 68)

62 (52, 69)

62 (52, 67)

Gender

 Male

376 (57.8%)

279 (59.4%)

97 (53.9%)

 Female

274 (42.2%)

191 (40.6%)

83 (46.1%)

BMI

 < 18.5

20 (3.1%)

14 (3.0%)

6 (3.3%)

 18.5–24

279 (42.9%)

203 (43.2%)

76 (42.2%)

 24–28

264 (40.6%)

189 (40.2%)

75 (41.7%)

 ≥ 28

87 (13.4%)

64 (13.6%)

23 (12.8%)

Smoking

 Yes

200 (30.8%)

150 (31.9%)

50 (27.8%)

 No

450 (69.2%)

320 (68.1%)

130 (72.2%)

Alcohol

 Yes

115 (17.7%)

89 (18.9%)

26 (14.4%)

 No

535 (82.3%)

381 (81.1%)

154 (85.6%)

Gross appearance

 Bulge

196 (30.2%)

139 (29.6%)

57 (31.7%)

 Infiltration or ulcer

454 (69.8%)

331 (70.4%)

123 (68.3%)

Histological type

 Adenocarcinoma

604 (92.9%)

437 (93.0%)

167 (92.8%)

 Mucinous adenocarcinoma or signet ring cell cancer

46 (7.1%)

33 (7.0%)

13 (7.2%)

T stage

 T1–T2

104 (22.1%)

104 (22.1%)

45 (25.0%)

 T3–T4

501 (77.1%)

366 (77.9%)

135 (75.0%)

N stage

 N0–N1

547 (84.2%)

394 (83.8%)

153 (85.0%)

 N2–N3

103 (15.8%)

76 (16.2%)

27 (15.0%)

TNM stage

 I–II

395 (60.8%)

284 (60.4%)

111 (61.7%)

 III

255 (39.2%)

186 (39.6%)

69 (38.3%)

Differentiated degree

 Well/moderate

103 (15.8%)

73 (15.5%)

30 (16.7%)

 Poor/undifferentiated

547 (84.2%)

397 (84.5%)

150 (83.3%)

Nerve invasion

 Positive

114 (17.5%)

84 (17.9%)

30 (16.7%)

 Negative

536 (82.5%)

386 (82.1%)

150 (83.3%)

Intravascular tumor emboli

 Positive

123 (18.9%)

87 (18.5%)

36 (20.0%)

 Negative

527 (81.1%)

383 (81.5%)

144 (80.0%)

CEA

 High

234 (36.0%)

171 (36.4%)

63 (35.0%)

 Normal

416 (64.0%)

299 (63.6%)

117 (65.0%)

ALB (g/L), median (IQR)

40.7 (38.0, 43.2)

40.6 (37.8, 43.2)

40.8 (38.5, 43.2)

PLT (109/L), median (IQR)

241 (199, 290)

240 (198, 290)

242 (203, 286)

NE (109/L), median (IQR)

3.60 (2.89, 4.43)

3.62 (2.92, 4.52)

3.53 (2.84, 4.28)

MONO (109/L), median (IQR)

0.45 (0.35, 0.56)

0.45 (0.35, 0.56)

0.45 (0.35, 0.56)

LY (109/L), median (IQR)

1.81 (1.46, 2.19)

1.79 (1.45, 2.19)

1.83 (1.49, 2.15)

  1. IQR interquartile range, BMI body mass index, CEA carcinoembryonic antigen, ALB albumin, PLT platelet count, NE neutrophil count, MONO monocyte count, LY lymphocyte count.
Back to article page